Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on longevity research and SIRT6-based gene therapies. This news page aggregates regulatory announcements and corporate updates related to Genflow’s scientific programs, intellectual property, and capital markets activity.
Readers can follow developments in Genflow’s gene therapy pipeline, including its 12‑month proof‑of‑concept clinical trial in aged dogs that evaluates a SIRT6‑centenarian gene therapy for age‑related decline. Company updates have highlighted dosing milestones, safety and tolerability observations in elderly dogs, and the design of blinded clinical assessments using biomarkers linked to sarcopenia, healthspan, and lifespan.
The news flow also covers Genflow’s plans to explore GF‑1002 in MASH (Metabolic Dysfunction‑Associated Steatohepatitis), reflecting its interest in metabolic and age‑related disorders. In addition, announcements detail progress in the company’s intellectual property strategy, such as European Patent Office publications recognizing the patentability of SIRT6 variant claims and the publication of a second European patent application titled “SIRT6 Variant for NASH.”
Investors and observers will also find information on equity issues, warrants, and voting rights, including share subscriptions, warrant terms, and total issued share capital figures disclosed for regulatory purposes. Notifications of major holdings and participation in sector events, such as the J.P. Morgan Healthcare Conference, appear in the same stream.
By reviewing the GENFF news page, users can see how Genflow communicates the evolution of its SIRT6 gene therapy platform, its animal health and human-focused programs, and its ongoing regulatory and capital markets disclosures.
Genflow Biosciences (OTCQB:GENFF), Europe's only public longevity company, reported progress on two key programs. For GF-1002, the company has initiated CMC work with Exothera for GMP-compliant clinical supply production, while conducting pivotal efficacy studies for MASH treatment through CRO partners Physiogenex and Accelera. This work supports their upcoming European Clinical Trial Authorisation submission.
For GF-1004, Genflow submitted a protocol amendment to their ongoing proof-of-concept trial in aged dogs, specifying IV dose rates for their SIRT6-centenarian gene therapy to enhance safety and delivery consistency. The trial, launched in March with Syngene, aims to evaluate the therapy's impact on age-related decline.
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has confirmed its previously announced €4 million non-dilutive grant from Belgium's Wallonia Region. The funding will support the development of GF-1002, the company's lead gene therapy candidate for treating Metabolic Associated Steatohepatitis (MASH).
The grant covers a three-year development program aligned with Genflow's clinical roadmap. While initial disbursement awaits administrative procedures, the company has ensured the GF-1002 program continues without interruption or delays to planned research and development activities.
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed a Master Service Agreement (MSA) with CER Groupe, a private Belgian research center. The agreement formalizes their existing partnership and establishes a framework for accelerating Genflow's pre-IND gene therapy programs. The collaboration will focus on developing, producing, and characterizing gene therapy candidates while implementing standardized project management systems. CER Groupe brings ISO and GxP-compliant facilities and integrated bioproduction and pre-clinical services to the partnership.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announces the advancement of its SIRT6-related patent application to the national examination phase by the Japanese Patent Office. The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was filed in May 2022 and is jointly owned by the University of Rochester, Columbia University, and Albert Einstein College of Medicine, with Genflow holding exclusive licensing rights.
The patent covers novel SIRT6 gene variants crucial for genomic stability, metabolic regulation, and healthy aging, forming the foundation of Genflow's therapeutic platform. This advancement in Japan, a key market with a rapidly aging population, represents a significant step in the company's international patent protection strategy.
Dr Moayyed Al-Qurtas has acquired a significant stake in Genflow Biosciences (GENFF), reaching a 4.45% ownership of voting rights in the company. The threshold crossing occurred on May 9, 2025, and was reported to the company on May 12, 2025. This notification was made in accordance with the UK's Disclosure Guidance and Transparency Rules (DTR5). The acquisition was made through direct ownership of shares, with no financial instruments or indirect holdings involved.
Genflow Biosciences, a UK-based longevity biotechnology company, has released its final results for 2024. The company, focused on developing therapies to counter aging effects, reported significant progress in its research programs.
Key highlights include advancing their MASH study towards pre-IND phase, receiving positive FDA feedback, and securing £1.4 million in funding through grants and equity. The company established two major collaborations supported by non-dilutive grants from the Belgian Government: a Sarcopenia research program with Revatis SA and an Exosome-mRNA project with EXO Biologics.
Financial results show cash reserves of £278,682, with research and development expenditure of £1,151,462. The company received grant income of £320,471 and completed two fundraising rounds. Looking ahead to 2025, Genflow plans to launch a clinical trial in aged dogs and develop a new ophthalmology program focusing on gene therapy for eye conditions.
Genflow Biosciences (GENFF) has entered into a strategic partnership with Heureka Labs, signing a Master Services Agreement on April 11, 2025. The collaboration provides Genflow access to Heureka's proprietary AI platform, specialized in analyzing genomic data and gene expression profiles.
The partnership will support Genflow's lead candidate GF-1002, a SIRT6-based gene therapy in preclinical evaluation, and may extend to other programs including those targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). Under the agreement, Genflow retains all IP rights.
Heureka Labs, a Duke University technology spin-off, offers an AI platform currently used by leading pharmaceutical companies to accelerate drug discovery through hypothesis generation and pattern recognition in biological data.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only public longevity company, has announced a new ophthalmology development program focusing on novel gene therapy using their proprietary Centenarian SIRT6 (cSIRT6) technology.
The program will utilize a specially designed non-viral vector for precise delivery of SIRT6 to the eye, targeting ocular conditions including corneal pathologies and glaucoma. The company has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector.
According to CEO Dr. Eric Leire, the eye's closed and accessible compartment makes it an ideal target for gene therapy, with SIRT6 showing promising potential in treating corneal endothelial disorders and glaucoma.